Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors

NCT07006727 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT07006727
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07006727 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Dosimetry, and Preliminary Activity of [225Ac]Ac-ETN029 in Patients With Advanced DLL3-expressing Solid Tumors
Lead sponsor
Novartis Pharmaceuticals
Phase
Phase 1
Overall status
Recruiting
Start date
October 16, 2025
Completion date
August 29, 2031
Enrollment
116 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

cervical neuroendocrine carcinoma, gastroenteropancreatic neuroendocrine carcinoma, genitourinary neuroendocrine carcinoma, large cell neuroendocrine carcinoma of the lung, medullary thyroid carcinoma, merkel cell carcinoma, neuroendocrine prostate cancer, non-prostate extrapulmonary neuroendocrine carcinoma, small cell lung carcinoma, thymic neuroendocrine carcinoma, unknown primary neuroendocrine carcinomas